Applied DNA Awarded NYC-Based ‘Return-to-Office’
April 06 2022 - 9:00AM
Business Wire
Health Services Contract
Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a
leader in cell-free, enzymatic DNA production, announced today that
its wholly-owned clinical laboratory subsidiary, Applied DNA
Clinical Labs, LLC (ADCL), has been awarded a safeCircle™ health
services contract from a New York City-based investment management
firm. Contract terms were not disclosed. The contract provides for
PCR-based COVID-19 testing and associated services for employees of
the client who are returning to in-person work, with services
slated to begin in April 2022. safeCircle is a fully integrated
health testing platform that offers a customized suite of services
to institutions and their personnel/members that encompasses:
program design, RT-PCR and rapid antigen testing, sample kit
distribution and collection, test site management, results
reporting to individuals and program administrators, facilities
access management, variant tracking, and vaccination documentation
management.
“After two years of remote work amid the COVID-19 pandemic,
corporations are moving to resume in-person work supported by
workforce health policies prioritizing health, safety, and
wellbeing. As mask mandates expire, safeCircle can help manage
workers’ increased risk of exposure. We believe that managing the
spread of current and any future COVID-19 variants through testing
even in an era of vaccine availability remains critical if offices
are once again to be destinations for collaboration and
connection,” stated Mike Munzer, executive director of Diagnostic
Sales at Applied DNA. “safeCircle is a rapidly deployed,
integrated, and cost-effective testing platform that can
accommodate companies’ unique return-to-work policies to help
mitigate exposure and give employees and employers peace of
mind.”
To learn more about safeCircle™: click here
About Applied DNA Sciences
Applied DNA is commercializing LinearDNA™, its proprietary,
large-scale polymerase chain reaction ("PCR")-based manufacturing
platform that allows for the large-scale cell-free production of
specific DNA sequences.
The LinearDNA platform has utility in the nucleic acid-based in
vitro diagnostics and preclinical nucleic acid-based drug
development and manufacturing market. The platform is used to
manufacture DNA for customers as components of in vitro diagnostic
tests and for preclinical nucleic acid-based drug development in
the fields of adoptive cell therapies (CAR T and TCR T therapies),
DNA vaccines (anti-viral and cancer), RNA therapies, clustered
regularly interspaced short palindromic repeats (CRISPR) based
therapies, and gene therapies.
The LinearDNA platform also has non-biologic applications, such
as supply chain security, anti-counterfeiting and anti-theft
technology. Key end-markets include textiles, pharmaceuticals and
nutraceuticals, among others.
Leveraging its deep expertise in nucleic acid-based
technologies, the Company has also established safeCircle™, a high-
turnkey solution for population-scale COVID-19 testing. safeCircle
is designed to look for infection within defined populations or
communities utilizing high throughput testing methodologies that
increase testing efficiencies and provide for rapid
turn-around-times.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
The Company's common stock is listed on NASDAQ under the ticker
symbol 'APDN,' and its publicly traded warrants are listed on OTC
under the ticker symbol 'APPDW.'
Applied DNA is a member of the Russell Microcap® Index.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
"forward-looking" in nature within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934 and the Private Securities Litigation Reform Act of
1995. Forward-looking statements describe Applied DNA's future
plans, projections, strategies, and expectations, and are based on
assumptions and involve a number of risks and uncertainties, many
of which are beyond the control of Applied DNA. Actual results
could differ materially from those projected due to its history of
net losses, limited financial resources, limited market acceptance,
the possibility that Applied DNA's assay kits or testing services
could become obsolete or have their utility diminished and the
unknown amount of revenues and profits that will results from
Applied DNA's testing contracts. Further, the uncertainties
inherent in research and development, future data and analysis,
including whether any of Applied DNA's or its partner's future
diagnostic candidates will advance further in the research process
or receiving authorization, clearance or approval from the FDA,
equivalent foreign regulatory agencies and/or the New York State
Department of Health (NYSDOH), and whether and when, if at all,
they will receive final authorization, clearance or approval from
the FDA, equivalent foreign regulatory agencies and/or NYSDOH, the
unknown outcome of any applications or requests to FDA, equivalent
foreign regulatory agencies and/or the NYSDOH, the unknown limited
duration of any EUAs from the FDA, changes in guidance promulgated
by the CDC, FDA, CMS an/or NYSDOH relating to COVID-19 testing,
disruptions in the supply of raw materials and supplies, continued
mutations of the SARS-CoV-2 virus, shifting review priorities of
FDA for COVID-19 EUA requests and when, if at all, any EUA request
will be reviewed by FDA, and various other factors detailed from
time to time in Applied DNA's SEC reports and filings, including
our Annual Report on Form 10-K filed on December 9, 2021, its
Quarterly Report on Form 10-Q filed on February 10, 2022 and other
reports we file with the SEC, which are available at www.sec.gov.
Applied DNA undertakes no obligation to update publicly any
forward-looking statements to reflect new information, events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events, unless otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220406005123/en/
Investor Relations: Sanjay M. Hurry, 917-733-5573,
sanjay.hurry@adnas.com Program: Mike Munzer, 631-240-8814,
mike.munzer@adnas.com Web: www.adnas.com Twitter:
@APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024